These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21269789)

  • 1. Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis.
    Li SK; Liddell MR; Wen H
    J Pharm Biomed Anal; 2011 Jun; 55(3):603-7. PubMed ID: 21269789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
    Nagpal M; Nagpal K; Nagpal PN
    Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iontophoretic transport of charged macromolecules across human sclera.
    Chopra P; Hao J; Li SK
    Int J Pharm; 2010 Mar; 388(1-2):107-13. PubMed ID: 20045044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab.
    Wen H; Hao J; Li SK
    J Pharm Sci; 2013 Mar; 102(3):892-903. PubMed ID: 23212655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debate on the various anti-vascular endothelial growth factor drugs.
    Khalili MR; Hosseini H
    Indian J Ophthalmol; 2008; 56(3):255-6; author reply 256. PubMed ID: 18417837
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of neovascular age-related macular degeneration with bevacizumab].
    Monzón Moreno A
    Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
    [No Abstract]   [Full Text] [Related]  

  • 11. In-vitro permeation of bevacizumab through human sclera: effect of iontophoresis application.
    Pescina S; Ferrari G; Govoni P; Macaluso C; Padula C; Santi P; Nicoli S
    J Pharm Pharmacol; 2010 Sep; 62(9):1189-94. PubMed ID: 20796199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
    Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [VEGF inhibitors in ophthalmology].
    Thys J; Dupont G; Rakic JM
    Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted pharmacotherapy of retinal diseases with ranibizumab.
    Campochiaro PA
    Drugs Today (Barc); 2007 Aug; 43(8):529-37. PubMed ID: 17925884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic antibodies in ophthalmology: old is new again.
    Magdelaine-Beuzelin C; Pinault C; Paintaud G; Watier H
    MAbs; 2010; 2(2):176-80. PubMed ID: 21358858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
    Adelman RA; Zheng Q; Mayer HR
    J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.
    Schmucker C; Ehlken C; Hansen LL; Antes G; Agostini HT; Lelgemann M
    Curr Opin Ophthalmol; 2010 May; 21(3):218-26. PubMed ID: 20393293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of neovascular age-related macular degeneration with pegaptanib and boosting with bevacizumab or ranibizumab as needed.
    Farah SE
    Ophthalmic Surg Lasers Imaging; 2008; 39(4):294-8. PubMed ID: 18717434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
    Chong V
    Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.